额外SNP提升前列腺癌多基因风险评分分层
本研究在欧裔男性中利用180个SNP构建多基因风险评分(PHS),通过LASSO正则化Cox回归在训练集(75,596人)筛选SNP并估计系数,在测试集(6,411人)评估性能。结果显示,含166个SNP的PHS166较原PHS46显著改善风险分层(HR95/50从3.72升至5.09,HR80/20从6.12升至9.45,HR20/50从0.41降至0.34),但PSA检测对临床显著前列腺癌的阳性预测值(PPV)无显著差异。
要点
- PHS166较PHS46显著改善前列腺癌风险分层,HR95/50、HR80/20升高,HR20/50降低。
- PSA检测对临床显著前列腺癌的阳性预测值(PPV)在PHS166与PHS46间无显著差异。
- 额外120个SNP的加入提升了风险分层能力,但未改善PSA检测的阳性预测值。
核心结论
- 纳入额外120个SNP的PHS166较PHS46显著改善前列腺癌风险分层,但PSA检测的阳性预测值无显著变化。
研究设计与样本
- 研究在欧裔男性中利用180个SNP构建PHS模型,采用LASSO正则化Cox回归在训练集(75,596人)筛选SNP并估计系数,在测试/验证集(6,411人)评估性能。
主要发现
- PHS166较PHS46显著改善风险分层:HR95/50从3.72升至5.09,HR80/20从6.12升至9.45,HR20/50从0.41降至0.34。
- PSA检测对临床显著前列腺癌的阳性预测值(PPV)在PHS166与PHS46间无显著差异。
关键数值与推荐
- PHS166在Cox模型中有166个SNP非零系数;HR95/50=5.09,HR80/20=9.45,HR20/50=0.34。
- PPV计算基于PHS最高20%(PPV80)和最高5%(PPV95)人群中PSA升高且活检诊断为临床显著前列腺癌的比例,但原文未报告具体数值。
临床怎么用
- PHS166可用于改善前列腺癌风险分层,识别高风险个体,但PSA检测的阳性预测值未提升,需结合其他指标综合评估。
局限性
- 研究仅纳入欧裔男性,结论外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polygenic hazard scores (PHS) can identify individuals with increased risk of prostate cancer. We estimated the benefit of additional SNPs on performance of a previously validated PHS (PHS46). MATERIALS AND METHOD: 180 SNPs, shown to be previously associated with prostate cancer, were used to develop a PHS model in men with European ancestry. A machine-learning approach, LASSO-regularized Cox regression, was used to select SNPs and to estimate their coefficients in the training set (75,596 men). Performance of the resulting model was evaluated in the testing/validation set (6,411 men) with two metrics: (1) hazard ratios (HRs) and (2) positive predictive value (PPV) of prostate-specific antigen (PSA) testing. HRs were estimated between individuals with PHS in the top 5% to those in the middle 40% (HR95/50), top 20% to bottom 20% (HR80/20), and bottom 20% to middle 40% (HR20/50). PPV was calculated for the top 20% (PPV80) and top 5% (PPV95) of PHS as the fraction of individuals with elevated PSA that were diagnosed with clinically significant prostate cancer on biopsy. RESULTS: 166 SNPs had non-zero coefficients in the Cox model (PHS166). All HR metrics showed significant improvements for PHS166 compared to PHS46: HR95/50 increased from 3.72 to 5.09, HR80/20 increased from 6.12 to 9.45, and HR20/50 decreased from 0.41 to 0.34. By contrast, no significant differences were observed in PPV of PSA testing for clinically significant prostate cancer. CONCLUSIONS: Incorporating 120 additional SNPs (PHS166 vs PHS46) significantly improved HRs for prostate cancer, while PPV of PSA testing remained the same.
引用
- Karunamuni RA, Huynh-Le MP, Fan CC, et al. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 33420416. doi:10.1038/s41391-020-00311-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。